Skip Navigation LinksHome > October/December 2012 - Volume 23 - Issue 4 > Pharmacotherapy of Pediatric Advanced Life Support and Toxic...
AACN Advanced Critical Care:
doi: 10.1097/NCI.0b013e31826b4c70
Symposium Pharmacotherapy for Pediatric Acute and Critical Care

Pharmacotherapy of Pediatric Advanced Life Support and Toxicological Emergencies

Dandeles, Lauren M. PharmD; Ohler, Kirsten H. PharmD

Section Editor(s): Pate, Mary Frances D. Earnest Alexander, Symposium Editors

Continued Education
Collapse Box


Guidelines for pediatric advanced life support have been available for nearly a quarter of a century. Recommendations for the pharmacological management of pediatric cardiac arrest have changed over these years. Several important differences have been observed between adult advanced cardiac life support and pediatric advanced life support that must be recognized when children require resuscitation, such as the cause of the arrest, age-specific monitoring parameters, weight-based medication dosing, and obstacles in obtaining venous access. To make matters more complicated, differences also exist across neonatal and pediatric age spectrums. In addition, some toxicological emergencies commonly occurring in children require pharmacological management with agents that have a unique mechanism of action for cardiac support.

© 2012 American Association of Critical–Care Nurses


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.